Ipamorelin + Tesamorelin: the stack guide
Ipamorelin plus Tesamorelin is a clean, research-backed GHRH + GHRP alternative to CJC-1295 + Ipamorelin. Tesamorelin has better clinical documentation than CJC-1295 (FDA approved for HIV-associated lipodystrophy), making this pair preferred by clinicians who want a more conservative compound profile.
Why Ipamorelin and Tesamorelin pair well
Tesamorelin is a stabilized GHRH(1-44) analog that raises baseline GH-releasing tone with a favorable safety record. Ipamorelin provides the pulsatile GHRP signal without cortisol or prolactin elevation. The combination produces a strong physiological GH pulse with well-characterized pharmacokinetics.
Suggested cadence
Tesamorelin 1–2 mg subcutaneous daily, plus Ipamorelin 200–300 mcg once or twice daily (pre-bed and/or post-workout). Cycles typically run 12–16 weeks with IGF-1 monitoring; breaks of 4+ weeks between cycles are standard.
This is informational only — dosing should always be individualized and discussed with a qualified clinician.
Reconstitution notes
Ipamorelin: A common ratio is 2 ml of bacteriostatic water for a 5 mg vial. Open the Ipamorelin calculator →
Tesamorelin: A common ratio is 2 ml of bacteriostatic water for a 5 mg vial. Open the Tesamorelin calculator →
Side effects to watch for
Tesamorelin reliably raises IGF-1 and can modestly increase fasting glucose — test quarterly if running long cycles. Injection-site redness is more common with Tesamorelin than with CJC-1295. Mild water retention in the first 2–3 weeks is typical.
The two compounds
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that mimics ghrelin at the GHSR-1a receptor. It is prized for stimulating GH releas…
Tesamorelin
Tesamorelin is a stabilized analog of human GHRH, FDA approved for reducing excess visceral adipose tissue in HIV-associated lipodystroph…
Track this stack on iPhone
Peptide Protocol schedules both compounds, calculates reconstitution, and rotates injection sites automatically.
See the app →Frequently asked questions
Why stack Ipamorelin with Tesamorelin?
Ipamorelin plus Tesamorelin is a clean, research-backed GHRH + GHRP alternative to CJC-1295 + Ipamorelin. Tesamorelin has better clinical documentation than CJC-1295 (FDA approved for HIV-associated lipodystrophy), making this pair preferred by clinicians who want a more conservative compound profile.
What is the typical Ipamorelin + Tesamorelin dose?
Tesamorelin 1–2 mg subcutaneous daily, plus Ipamorelin 200–300 mcg once or twice daily (pre-bed and/or post-workout). Cycles typically run 12–16 weeks with IGF-1 monitoring; breaks of 4+ weeks between cycles are standard.
Can you inject Ipamorelin and Tesamorelin in the same syringe?
Many users co-administer GHRH + GHRP pairs (like CJC-1295 + Ipamorelin) in a single syringe to reduce injections, since both are stable in bacteriostatic water for short periods. For other pairs, draw and inject separately to minimize compatibility risk and to attribute any reaction to the correct compound.
What side effects should I watch for?
Tesamorelin reliably raises IGF-1 and can modestly increase fasting glucose — test quarterly if running long cycles. Injection-site redness is more common with Tesamorelin than with CJC-1295. Mild water retention in the first 2–3 weeks is typical.
How long should a Ipamorelin + Tesamorelin cycle run?
Most user-reported cycles run 4–12 weeks depending on the goal. GH-axis stacks are typically cycled with a break of 4 weeks or more between blocks to preserve receptor sensitivity. Soft-tissue stacks are usually run continuously until the injury resolves.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.